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Glutathione diminishes the anti-tumour activity of
4-hydroperoxycyclophosphamide by stabilising its spontaneous
breakdown to alkylating metabolites
F.Y.F. Lee
Experimental Therapeutics Division and Department ofRadiation Oncology, University ofRochester Cancer Center, Rochester,
NY 14642, USA.
Summary Evidence was obtained showing that GSH protects against the cytotoxicity of 4-
hydroperoxycyclophosphamide (4-OOH-CP) by minimizing the spontaneous fission of 4-
hydroxycyclophosphamide (4-OH-CP), its breakdown product, to the ultimate toxic species, phosphoramide
mustard (PM). This conclusion was borne out in two series of experiments. The first demonstrated that
4-OH-CP was progressively more stable in aqueous solutions containing increasing concentrations of GSH.
The second series of experiments were carried out with tumour cell lines with high (SKOV-3) and low (KHT)
GSH contents. The cytotoxicity of 4-OOH-CP, a stable precursor that rapidly gives rise to 4-OH-CP
spontaneously under physiological conditions, was enhanced in GSH-depleted SKOV-3 cells, but was
unchanged in GSH-depleted KHT cells. It is concluded that the high GSH content of SKOV-3 cells provides a
significant protection against 4-OH-CP by limiting the breakdown/activation of 4-OH-CP. Deschloro-4-
hydroperoxycyclophosphamide (deschloro-4-OOH-CP), an analogue of 4-OOH-CP that generates acrolein
(AC) but not PM in the spontaneous fission reaction, is essentially non-toxic when compared with 4-OOH-CP
but is equally potent in depleting GSH. It is postulated that AC may promote the cytotoxicity of the parent
4-OH-CP by depleting cellular GSH. Consequently, the stabilising influence of GSH on 4-OH-CP is removed,
leading to increased formation of PM, the ultimate cytotoxic agent.
There is considerable evidence that glutathione (GSH) plays
a major role in protecting tumour cells against the cytotox-
icity of the oxazaphosphorines, including cyclophosphamide
(CP) and its active congener, 4-hydroperoxycyclophosph-
amide (4-OOH-CP), both in vitro (Russo et al., 1986; Crook
et al., 1986a) and in vivo (Gurtoo et al., 1981; Carmichael
et al., 1986b; Ono & Shrieve, 1987). Recently, in a study of
17 tumour cell lines, we noted a close correlation between the
chemosensitivity of these cell lines to 4-OOH-CP and their
steady-state GSH level (Lee et al., 1990). It was further
noted that whilst GSH 'detoxifies' 4-OOH-CP, 4-OOH-CP in
turn depletes GSH. In fact, 4-OOH-CP is at toxic concen-
trations a potent depletor of cellular GSH. Most important,
the tumour cell GSH depletion and the lethality produced by
4-OOH-CP appear to be linked events. Significant 4-OOH-
CP cytotoxicity was invariably associated with GSH de-
pletion, and vice versa. In the present paper, evidence is
presented showing that GSH modulates the cytotoxicity of
4-OOH-CP by participating in chemical reactions at three
separate locations in the metabolic pathway of 4-OH-CP, its
spontaneous breakdown product. (4-OOH-CP gives rise
rapidly to 4-OH-CP following dissolution without any
enzymic involvement and may be regarded as equivalent to
4-OH-CP pharmacologically (Sladek, 1987). 4-OOH-CP is
the preferred 'activated' cyclophosphamide for routine use
only because of its higher stability in crystalline state and
easier synthesis.) 4-OH-CP, sometimes called 'activated'
cyclophosphamide, is formed from the hydroxylation of CP
by the hepatic mixed-function oxidases (Figure 1). 4-OH-CP
is in reality the 'transport' form of CP since it is in this form
that active CP reaches the target tumour cells (Sladek, 1987).
Intracellular 4-OH-CP is in equilibrium with its ring-opened
tautomer aldophosphamide (AP). The fate of AP may follow
one of three main competing metabolic pathways: (1) spon-
taneous fission to acrolein (AC) and phosphoramide mustard
(PM), (2) enzymatic transformation to the non-toxic car-
boxyphosphamide (CBP), or (3) reaction with thiols in a
futile cycle to form hemithioacetal, which then undergoes
Received 8 March 1990; and in revised form 19 July 1990.
ring-closure and hydroxylation to produce once again the
parent 4-OH-CP. As depicted in Figure 1, glutathione (GSH)
can participate in conjugative reactions at three separate
locations that may have considerable influence on the even-
tual cytotoxicity of 4-OH-CP. (1) Reaction with AP as des-
cribed above which shifts the pseudoequilibrium between
4-OH-CP and AP in favour of the former and thereby cur-
tails the spontaneous degradation of AP to toxic metabolites.
GSH also reacts irreversibly with the toxic metabolites AC
and PM, but particularly the former (2 and 3) (Gurtoo et al.,
1981). In the accompanying paper we demonstrated that
when the combined rates of the conjugation reactions exceed
the rate of GSH recovery, i.e. when GSH is being depleted,
significant cytotoxicity inevitably occurs. The present findings
suggest that GSH depletion impacts directly on the cytotoxic
potency of 4-OH-CP by destabilising AP (see Figure 1). The
destabilisation of AP results in an increase in the rate of the
major toxification reaction, i.e., spontaneous breakdown of
AP to PM and AC, which further depletes GSH. Conditions
are thus set for a catastrophic cycle of GSH depletion and
4-OH-CP 'activation', leading inexorably to cell death.
Materials and methods
Cell culturing
The SKOV-3 and MLS human ovarian cancer lines were
maintained as monolayer cultures in alpha-MEM medium
(Gibco), supplemented with 10% fetal calf serum (FCS),
5 mM glutamine and 10 mM HEPES, at 37°C in a 5% C02/ 95% air atmosphere.
Drugs anddrug treatment
4-hydroperoxycyclophosphamide (4-OOH-CP) and deschloro-
4-hydroperoxycyclophosphamide (deschloro-4-OOH-CP) were
generous gifts from Dr R. Borch (Department of Pharma-
cology, University of Rochester) and Dr P. Hilgard (ASTA-
Werke Bielefeld, FDR). L-buthionine sulphoximine was
obtained from Chemical Dynamic Corp. (Southfield, NJ,
USA). 4-(p-nitrobenylz) pyridine was purchased from Sigma
Chemical Company.
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Figure 1 The metabolism of cyclophosphamide (simplified). Three major reactions involving GSH are shown: two on the left panel, one on the bottom right. Abbreviations are: CP, cyclophosphamide; 4-OH-CP, 4- hydroxycyclophosphamide; AP, aldophosphamide; AC, acrolein; PM, phsophoramide mustard; CBP, carboxy- phosphamide; ADH, aldehyde dehydrogenase; 4-SH-CP, 4-thiocyclophosphamide.
Mice and tumours
Inbred female C3H/HeJ mice were supplied by Jackson
Laboratories (Bar Harbor, ME, USA). The KHT murine
fibrosarcomas, originating from a spontaneous tumour in a
female C3H/He mouse (Kallman et al., 1967), were main-
tained in vivo by serial transplantation into the gastrocnemius
muscles of recipients. A single cell suspension was obtained
by a mechanical dissociation procedure (Siemann et al., 1981)
and 1-2 x 105 cells were inoculated.
Centrifugal elutriation
The detailed procedures for the purification of tumour cells
from admixtures of host and tumour cells have been reported
(Siemann et al., 1981). Briefly, a cell mixture (1-2 x 108)
suspended in 20 ml of a-MEM medium was loaded into the
separation chamber of a Beckman JE6 elutriator system,
spinning at a speed of 4,000 r.p.m. and at a flow rate of
36 ml min-' at the time of cell loading. Initially, red blood
cells and cell debris were eluted. In the second cell collection
stage, the flow rate was increased to 45 ml min-' and the
rotor speed was decreased in 6 intervals to 2,700 r.p.m. A
variable number (3-5) of 40-ml fractions were collected at
each interval. This stage removed most of the host cells. In
the third stage, tumour cells remaining in the chamber were
eluted by decreasing the rotor speed to 0 r.p.m. The tumour
cell purity in each fraction was confirmed by cell volume
measurement with a Coulter Counter channelyser and by DNA content analysis using flow cytometric techniques.
Glutathione analysis
The reversed-phase HPLC technique for the analysis of GSH
was as described previously (Lee et al., 1989).
Reaction kinetics of4-OH-CP with glutathione
In an aqueous environment, 4-OH-CP degrades spontan-
eously to the toxic metabolites, phosphoramide mustard
(PM) and acrolein (AC). These reactive metabolites, once
formed, will react irreversibly and rapidly with GSH, causing its eventual depletion. In the presence of L-BSO, which
inhibits completely any de novo synthesis ofGSH, the rate by which GSH is depleted provides a measure of the relative
rate of formation of the reactive metabolites, all else being equal. In relative terms, the more stable the 4-OH-CP, the
less will be the amount of reactive metabolites formed, and
the slower will be the rate of GSH depletion. In these
experiments, GSH depletion was followed by the direct
measurement of GSH in the homogenates of SKOV-3 and
KHT cells (treated respectively with 100 ILM and 14.7 pLM 4-OOH-CP). The concentrations of 4-OOH-CP were chosen
to yield similar lethality in both cell lines (approx. 3 log cell
kill). The dependence of the depletion kinetics on the inital
GSH concentration was determined. SKOV-3 cells with a
range of initial GSH contents were obtained by pretreatment of monolayer cell cultures with 1 mM L-BSO for various
times (up to 6h). For the KHT tumour cells, mice bearing leg tumours were treated with L-BSO (2.5 mmol kg-') from 1 to 4 h before tumour dissociation. Single cell suspensions
were then prepared as described above. Cells, at a concentra-
tion of 4 x 105ml-', were suspended in complete a-MEM
medium containing 1 mM L-BSO in a type I vial as described
previously (Whillans & Rauth, 1980). 4-OOH-CP was then
added and aliquots of cells were withdrawn every 10 min for
GSH analysis. The time taken to deplete 20% of the initial
cellular GSH (t20) was determined. The apparent rate (vapp) of
toxic metabolite formation in tumour cells having an initial
steady-state GSH content of [GSH]i is thus given by the
equation:
_ [GSH]i x 0.2
t2O
Measurement ofalkylating capacity
The method of Friedman and Boger (Friedman & Boger, 1961) was used to determined the total concentration of alkylating and potential alkylating compounds in homogen- ates of 4-OOH-CP treated cells after acid hydrolysis in 1 M HCI at 100°C for 10 min. Tumour cells were homogenised in 0.05 mM phosphate-buffered solution (PBS), pH 7.4, at a
concentration of I07ml-' PBS. An 0.2 ml aliquot of 1 M HCI solution was added to 1 ml of cell homogenate. The mixture was boiled (100°C) for 10min, cooled, and centri- fuged for I min in an Eppendorf microcentrifuge. The super- natant was diluted to 3.0 ml with distilled water. A 1 ml aliquot of 0.2 M acetate buffer, pH4.6, was added and the pH adjusted to 4.6 by the addition of sodium hydroxide (1 M). Finally, the assay was carried out as previously des- cribed (Friedman & Boger, 1961).GLUTATHIONE AND 4-HYDROPEROXYCYCLOPHOSPHAMIDE 47
Results
Enhancement by L-BSO of4-OOH-CP cytotoxicity and GSH
depletion activity
The impact of cellular GSH content modulation by L-BSO
on the 4-OOH-CP sensitivity of two cell lines was studied. (1)
SKOV-3, a human ovarian tumour line, contains a very high
level of GSH and exhibits considerable resistance to the
action of 4-OOH-CP. (2) KHT, a murine fibrosarcoma line,
grows in vivo as a solid tumour and contains very low GSH
level and exhibits exquisite sensitivity to 4-OOH-CP. For the
SKOV-3, treatment with 1 mM L-BSO 1 h prior to 4-OOH-
CP exposure resulted in a greater degree of cell kill than
treatment with 4-OOH-CP alone (Figure 2a). The 4-OOH-CP
dose enhancement factor resulting from L-BSO treatment was
dependent on the end-point chosen. At survival levels of 0.1
and 0.01, these factors were 1.63 and 1.86, respectively. In
contrast, KHT cells depleted of GSH did not show enhanced
sensitivity to 4-OOH-CP (Figure 2b). Treatment of cells with
L-BSO (1 mM) alone for 4 h was without toxicity (Lee et al.,
1988; Siemann et al., 1989).
The above results show that the cytotoxicity of 4-OOH-CP
can be modulated by altering the cellular GSH content.
Additionally, in the companion paper, toxic concentrations
of 4-OOH-CP were demonstrated to be an effective depletor
of cellular GSH (Lee et al., 1990). Most importantly, the
cytotoxic and GSH-reducing effects of 4-OOH-CP are closely
related. To study further this relationship, we investigated
whether or not prior reduction of GSH content by L-BSO
affects the ability of 4-OOH-CP to deplete GSH subsequent-
ly. Figure 3 shows the depleting effects of 4-OOH-CP treat-
ment alone on the cellular GSH content of SKOV-3 (a) and
KHT (b) tumour cells. Toxic concentrations (i.e. concentra-
tions causing >,I log cell kill, see Figure 2a and b of
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Figure 3 The effects of a 3 h exposure to 4-OOH-CP, with or
without prior GSH depletion by L-BSO, on the cellular GSH
content of (a) SKOV-3 human ovarian cancer cell line, and (b)
KHT murine sarcoma cell line. Error bars represent±s.d.
4-OOH-CP caused the GSH contents of both cell lines to be
severely reduced; non-toxic concentrations of4-OOH-CP had
no such effect. Cells treated with combined L-BSO plus 4-
OOH-CP were much more severely depleted of GSH than
cells treated with 4-OOH-CP alone. For SKOV-3, but not
KHT, the net reduction of GSH was significantly greater
than the sum of the separate effects of the two agents. For
example, exposure to 25 and 50gM of 4-OOH-CP for 3 h
reduced the cellular GSH content of SKOV-3 by 13.1 and
20.5 fmol respectively. In comparison, the reductions in GSH
content with combined L-BSO plus 4-OOH-CP treatment was
of greater magnitude, being 23.2 and 27.3 fmol respectively.
The effects ofdeschloro-4-hydroperoxycyclophosphamide
To determine whether GSH depletion per se was toxic, cells
were treated with deschloro-4-hydroperoxycyclophosphamide
(deschloro-4-OOH-CP), a cogener of 4-OOH-CP that retains
the ability to generate the GSH binding acrolein but pos-
sesses little alkylating activity. Figure 4a shows the concen-
tration-cytotoxicity relationship of deschloro-4-OOH-CP in
the MLS cell line. At an equivalent level ofcytotoxicity (10%
survival), 4-OOH-CP was at least 10 times more effective
than deschloro-4-OOH-CP as a cytotoxic agent. In terms of
GSH depletion, however (Figure 4b), 4-OOH-CP was only
slightly more effective (less than -1.5 times). These results
strongly suggest that GSH depletion per se was not the major
mechanism of 4-OOH-CP cytotoxicity.
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Figure 2 The effects of L-BSO pretreatment on the cytotoxicity
of4-OOH-CP in (a) SKOV-3 human ovarian cancer cell line, and
(b) KHT murine sarcoma cell line. Error bars represent±s.d.
The inverse dependence ofthe rate ofreactive metabolites
formation on GSH content
In these experiments, tumour cells with a range of initial
GSH contents were obtained by pretreatment of cells with
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Figure 4 Comparison of the (a) cytotoxicity and (b) GSH deple-
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Figure 5 The influence of altering the initial GSH content of
cells by prior L-BSO pretreatment of various duration on the
subsequent kinetics of GSH depletion by 4-OOH-CP in two
tumour cell lines. (a) SKOV-3 human ovarian cancer cell line,
and (b) KHT murine sarcoma cell line. Inserts depict the GSH
depletion kinetics by L-BSO alone. Individual symbols are the
mean of triplicate determinations.
L-BSO (1 mM) for various times before exposure to 4-OOH-
CP. The relative rate of formation of the toxic, reactive
metabolites in the different cell populations having differing
levels of GSH was determined by monitoring the rate of
GSH depletion. Reactive metabolites (mainly acrolein) react
with and deplete GSH rapidly following their formation
(Figure 5a and b). In SKOV-3 cells, the rate of toxic
metabolites formation was found to be inversely proportional
to the initial GSH concentration at the time of 4-OOH-CP
exposure (Figure 6a). In KHT cells, which have much lower
steady state GSH content than SKOV-3 cells, lowering of the
GSH content by L-BSO appeared not to affect the rate of
toxification of 4-OOH-CP (Figure 6b).
Effects ofcellular GSH content on the alkylating capacity of
4-OOH-CP in cells
The mode of protection by GSH was investigated in these
series of experiments. It was found that manipulation of the
level ofcellular GSH by pretreatment ofcells with L-BSO did
not alter the level of the intracellular alkylating capacity of
4-OOH-CP measured at various times following drug expo-
sure (Figure 7a). These results suggest that GSH did not
protect against the cytotoxicity of 4-OOH-CP by (1) affecting
drug uptake or accumulation, or (2) reacting irreversibly with
4-OOH-CP. However, GSH did have a dramatic effect on the
stability of 4-OOH-CP in aqueous solution, preventing very
effectively, in a concentration dependent manner (Figure 7b),
the spontaneous breakdown of 4-OOH-CP to toxic products
(Draeger et al., 1976; Zon et al., 1984).
Discussion
GSH has been shown in numerous studies to protect tumour
cells against the cytotoxic action of 4-OOH-CP (Russo et al.,
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Figure 6 The relationship between the initial GSH content of
cells and the rate of GSH depletion by 4-OOH-CP in two tumour
cell lines. Concentrations of 4-OOH-CP used were 100 and
14.7gM for the SKOV-3 and KHT tumour cell lines respectively.
Error bars represent±s.d. of three repeat experiments.
1986; Crook et al., 1986; Gurtoo et al., 1981; Carmichael et
al., 1986b; Ono & Shrieve, 1987). In the present investigation,
evidence was obtained that led to the formulation of a
hypothetical model which accounts mechanistically for this
protective role of GSH. It is proposed that GSH protects via
an efficient two-prong mechanism. Firstly, GSH provides
protection by direct irreversible conjugation of the toxic
metabolites. This mechanism, common to many electrophilic
alkylating agents used in cancer chemotherapy, has been
thoroughly described (for reviews see Arrick & Nathan, 1984;
Jocelyn, 1972). The second mechanism, unique to 4-OH-CP,
involves the reversible reaction of GSH with AP, the ring-
opened isomer of 4-OOH-CP, to form hemithioacetal fol-
lowed by ring-closure and hydroxylation to produce theGLUTATHIONE AND 4-HYDROPEROXYCYCLOPHOSPHAMIDE 49
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Figure 7 (a) The effects of prior GSH depletion by L-BSO (4 h)
on the intracellular alkylating capacity in SKOV-3 cells following
4-OOH-CP exposure (200gM). Filled circles, controls; open
circles, with L-BSO pretreatment. (b) The influence of GSH
concentration on the alkylating capacity of 4-OOH-CP (200 jAM
in aqueous phosphate-buffered solution, pH 7.4. Alkylating capa-
city was determined by the 4-nitrobenzyl-pyridin (NBP)-test.
Each symbol represents the average of triplicate determinations.
parent 4-OH-CP once again (Figure 1). This cyclic reaction
has been well studied using 31P NMR spectroscopy (Zon et
al., 1984; Kwon et al., 1987). The effect of this reaction is the
stabilisation of 4-OH-CP from spontaneous degradation to
toxic metabolites (Figures 6a and 7b). The importance of
GSH as a determinant of cellular sensitivity to cyclophos-
phamide and its activated metabolite, 4-OH-CP, is likely due
to this two-tier mechanism.
Interestingly, the decelerating effect of GSH on the spon-
taneous degradation of 4-OH-CP appeared to be effective
only at high GSH concentration. Thus, L-BSO was effective
in enhancing the cytotoxicity and spontaneous degradation
of 4-OH-CP for SKOV-3 cells, which have high GSH con-
tent, but was ineffective on both counts for KHT cells, which
have low GSH content. This concentration dependent char-
acteristic of GSH protection may have important impli-
cations regarding the use of L-BSO in combination with
cyclophosphamide in cancer chemotherapy. It may be that
this combination should optimally be used for resistant
tumours with high GSH contents (Lee et al., 1990), but may
have little additional value, over treatment with cyclophos-
phamide alone, for sensitive tumours with low GSH content.
Similarly, critical normal tissues, such as the bone marrow,
containing lower GSH contents than tumours (Lee et al.,
1989) may be preferentially spared vis-a-vis tumours.
It should be noted that Draeger et al. (1976) has previously
reported that GSH and other thiols could stabilize the
alkylating capacity of 4-OH-CP by the reversible formation
of 4-(alkylthio)cyclophosphamide. Zon et al. (1984) and
Kwon et al. (1987) had subsequently confirmed this result
using 3lP NMR spectroscopy. It was concluded that 4-OH-
CP underwent slow ring opening to AP followed by facile
formation of hemithioacetal, which then cyclised to 4-
thiocyclophosphamide adducts (Kwon et al., 1987). The pres-
ent study extends these findings and, in addition, provides
the first demonstration that the stabilising effects of GSH
also occur within intact tumour cells. The toxification of
4-OH-CP takes place via the tautomer AP. GSH, via the
futile cyclic reactions described above (Figure 1) shifts the
tautomerism pseudoequilibrium between 4-OH-CP and AP in
favour of the former tautomer. This has the effect of reduc-
ing the rate of formation of AC and PM, the 'ultimate toxic
metabolite' (Connors et al., 1974; Sladek, 1987).
The pivotal role of GSH was well illustrated in the com-
panion study in which the chemosensitivity and GSH status
of each of 17 tumour cell lines was determined. A significant
direct correlation (r = 0.84, P = 0.05) was observed between
GSH content and resistance to 4-OOH-CP (Lee et al., 1990).
It was also found that the GSH status of cells treated with
4-OOH-CP was an extremely effective predictor ofchemosen-
sitivity. The occurrence of a significant reduction of tumour
cell reproductive capacity was always accompanied by sub-
stantial depletion of cellular GSH, and vice versa. The pre-
sent model provides a ready explanation for the effectiveness
of GSH status in predicting for cellular chemosensitivity to
4-OOH-CP. For a given cell line treated with a subtoxic dose
of 4-OOH-CP, the stabilisation effect of GSH is sufficient to
keep the formation of PM and AC to a minimum. Conse-
quently the intracellular GSH content remains relatively
unchanged following drug exposure. With increasing drug
dose however, considerable amounts of toxic metabolites are
formed. As a result (1) the intracellular GSH content begins
to be depleted which will then further destabilise 4-OH-CP,
and (2) the tautomerism pseudoequilibrium between 4-OH-
CP and AP shifts progressively in favour of AP which will
then further promote the formation of PM and AC. This
vicious cycle of destabilisation and toxic metabolite forma-
tion is likely to rapidly lead to cell death.
It should be noted that in the formulation of the present
model we have made two important assumptions: (1) The
quantity of the ultimate alkylating metabolite (PM) formed
during drug exposure is the dominant factor governing cellu-
lar chemosensitivity to 4-OH-CP. In this regard, it should be
noted that factors others than GSH per se may also play
significant roles in determining chemosensitivity by modu-
lating PM formation. Two such factors are the enzymes
aldehyde dehydrogenase and glutathione S-transferase.
These enzymes have been shown to confer resistance to
cyclophosphamide in some tumours and normal tissues
(Sladek, 1987; Hilton, 1984; Carmichael et al., 1986a;
McGown & Fox, 1986). A cell line with higher activity of
these enzymes may be able to detoxify AP more efficiently,
thus minimising toxic metabolites formation (see Figure 1)
and maintaining the GSH status quo. It is probably for this
reason that monitoring the changes in GSH status appears to
be better than monitoring absolute GSH content per se as a
method ofchemosensitivity prediction for 4-OOH-CP (Lee et
al., 1990). (2) It is also implicit in the proposed model that
the in vitro thiol-reactive effects of 4-OH-CP and its metabo-
lites can be extrapolated to in vivo conditions. Under some
conditions, this may not necessarily be the case. It has been
suggested that thiol-reactive agents might behave differently
in vivo as compared to in vitro because of differences in the
relative amount of thiols versus thiol-reactive agents present
under the two conditions (Wardman & Clarke, 1987). For
two reasons, however, it is believed that in vitro-in vivo
extrapolation is justified for 4-OH-CP and its metabolites.
Firstly, cyclophosphamide administration in vivo has been
shown to cause GSH depletion in vivo (Adams et al., 1986;
Carmichael et al., 1986a). Secondly, the important reversible
equilibria in the proposed reaction scheme are probably ade-
quately modelled in vitro, since relevant concentrations of the
thiol-reactive agent have been used.
The proposed model also defines the precise role of acro-
lein in the overall activity of4-OH-CP. A number of puzzling
observations have long fueled the debate as to which
metabolites of CP are responsible for its cytotoxic activity
(Sladek, 1987) and oncostatic specificity (Sladek, 1987;
Hohorst et al., 1976). Even though PM is now generally
regarded as the ultimate alkylating metabolite responsible for
the in vivo and in vitro cytotoxic activity of CP and 4-OH-CP
(Brock, 1976; Struck et al., 1975), the fact that its cytotoxic
activity and oncostatic specificity is much inferior, on a
molar basis, to CP and 4-OH-CP (Brock, 1976; Hohorst et50 F.Y.F. LEE
al., 1976; Alberts et al., 1984) remains unexplained. Exhaus-
tive investigation had uncovered no other metabolites of
significant cytotoxicity (Sladex, 1987), or which were able to
form inter-strand DNA crosslinks (Erickson et al., 1980;
Cairney et al., 1984). The basis of these paradoxical findings
has frequently been attributed to the presumption, never
conclusively proven, that PM has poor cell membrane trans-
port characteristics (Hohorst et al., 1976; Alberts et al.,
1984). The presence results suggest another, though not
mutually exclusive, explanation: 4-OH-CP possesses superior
cytotoxic activity to PM because of its ability to generate not
only PM but also acrolein which, though not cytotoxic itself,
augments the cytotoxic activity of 4-OH-CP. The possibility
of such a sensitising action has been suggested by Alarcon
and Meienhofer (1971) for acrolein, but no supporting
evidence has been presented. In agreement with previous
findings (Brock, 1976; Wrabetz et al., 1980), we have also
demonstrated the relative lack of toxicity of acrolein (Figure
4a). Thus, deschloro-4-hydroperoxycyclophosphamide, which
has its bis-(P-chloroethyl)amine group replaced by
diethylamine, produced acrolein (Alarcon & Meienhofer,
1971) and depleted cellular GSH as efficiently as 4-OOH-CP
(Figure 4b), but was non-cytotoxic because it cannot give rise
to PM (Figure 4a). The present model suggests that acrolein
enhances the cytotoxicity of PM via the following sequence
of events: (1) GSH depletion, (2) progressive destabilization
of 4-OH-CP, and finally (3) enhancement of PM formation.
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